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Dilated cardiomyopathy amongst children (pediatric cardiomyopathy, pediatric CM) is
associated with a high morbidity and mortality. Because little is known about the
pathophysiology of pediatric CM, treatment is largely based on adult heart failure therapy.
The reason for high morbidity and mortality is largely unknown as well as data on
cellular pathomechanisms is limited. Here, we assessed cardiomyocyte contractility
and protein expression to define cellular pathomechanisms in pediatric CM. Explanted
heart tissue of 11 pediatric CM patients and 18 controls was studied. Contractility was
measured in single membrane-permeabilized cardiomyocytes and protein expression
was assessed with gel electrophoresis and western blot analysis. We observed increased
Ca2+-sensitivity of myofilaments which was due to hypophosphorylation of cardiac
troponin I, a feature commonly observed in adult DCM. We also found a significantly
reduced maximal force generating capacity of pediatric CM cardiomyocytes, as well as a
reduced passive force development over a range of sarcomere lengths. Myofibril density
was reduced in pediatric CM compared to controls. Correction of maximal force and
passive force for myofibril density normalized forces in pediatric CM cardiomyocytes
to control values. This implies that the hypocontractility was caused by the reduction
in myofibril density. Unlike in adult DCM we did not find an increase in compliant titin
isoform expression in end-stage pediatric CM. The limited ability of pediatric CM patients
to maintain myofibril density might have contributed to their early disease onset and
severity.
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INTRODUCTION
Disease Progression in Pediatric Cardiomyopathy
Dilated cardiomyopathy (DCM) is a cardiac disease characterized by dilatation of the
(left) ventricle and systolic dysfunction. A genetic cause is found in 20–50% of DCM
cases (Hershberger et al., 2010; Herman et al., 2012; van Spaendonck-Zwarts et al., 2013).
The disease often develops in adulthood and treatment is currently only able to slow
down disease progression (Hershberger et al., 2013). In children, DCM is a rare disease
with an annual incidence estimated around 0.6/100,000 (Towbin et al., 2006). In two
large studies the 1- and 5-year transplantation-free survival rates have been reported to
be only 69–74 and 54–65%, respectively (Towbin et al., 2006; Alexander et al., 2013).
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The rate of severe adverse events is low 5 years after presentation
(Alexander et al., 2013) and most children die or receive cardiac
transplantation because of pump failure. The 5-year cumulative
incidence rate of sudden cardiac death is relatively low (2.4%;
Pahl et al., 2012). Poor prognosis in pediatric DCM patients
was associated with thin left ventricular (LV) wall (LV posterior
wall thickness z-score<− 1.7) and age <13.1 years at time of
diagnosis (Towbin et al., 2006; Pahl et al., 2012; Alexander et al.,
2013). In contrast to adult DCM, pediatric CM can be reversible
as in 22% of patients a full recovery has been reported (Everitt
et al., 2014). The aggressive nature of pediatric DCM and the
contradictory relative high recovery rate was also reported in
a recent Dutch study with a 1- and 5-year survival rate of 85
and 84%, respectively, which implies that most patients died
within the first year after diagnosis (den Boer et al., 2015). A
low transplantation rate in the 1st year after presentation and a
38% recovery rate, of which 50% within 1 year, was reported in
this study as well (den Boer et al., 2015). These studies together
show that there’s little difference in mortality after 1 and after 5
years in pediatric CM which implies that most events occur in
the first year. This is different compared to adult DCM in which
a slow disease progression and low recovery rate is more common
(Felker et al., 2000).
Pathogenesis of Pediatric Cardiomyopathy
Determinants underlying the highly diverse response to therapy,
recovery rates and mortality are largely unknown. While
several pathomechanisms have been elucidated in adult DCM,
knowledge of pathogenesis which underlies the aggressive
progression of DCM at young age is scarce. A recent study
showed that pediatric DCM patients show a different gene
expression profile compared to adult onset DCM (Tatman
et al., 2017). This study showed that pediatric CM samples
were characterized by an expression profile that reflected a
more undifferentiated cellular state, and showed a reduced
hypertrophic response compared to adult DCM (Tatman et al.,
2017). In order to understand why pediatric CM patients
show diverse responses to therapy and different recovery and
mortality rates compared to adult DCM, it is important to
understand which cellular processes are changed in pediatric CM.
However, since pediatric CM is rare and cardiac tissue from these
patients is scarce, limited information is available on the cellular
pathogenesis which underlies this disease.
In this study we explored the cellular phenotype of
end-stage pediatric CM samples. We combined functional
measurements in single isolated cardiomyocytes with protein
analyses and electron microscopy in a unique collection of
pediatric CM samples. Our studies revealed greatly reduced
force generating capacity of single cardiomyocytes caused by a
significant reduction in myofibril density. We observed troponin
I hypophosphorylation which was associated with increased
myofilament Ca2+-sensitivity and impaired myofilament length-
dependent activation. We did not find an increase in compliant
titin isoform in the pediatric samples, which is a common
form of disease remodeling in various forms of adult heart
failure (Makarenko et al., 2004; Nagueh et al., 2004; Bollen
et al., 2017b). However, we did find a large variation in titin
isoform composition in the pediatric CM group. Overall, our data
indicate that the pediatric CM heart that progresses to end-stage
failure has limited capacity to adequately respond to increased
wall stress.
METHODS
Clinical Characteristics
Echocardiographic examinations were performed in a uniform
way. All children were at rest and in sinus rhythm during
examination and a complete 2-dimensional echocardiographic
study was performed. M-mode of the parasternal long-axis was
used to measure LV posterior wall in systole (LVPWs), LV
posterior wall in diastole (LVPWd), LV end diastolic diameter
(LVEDD), and LV end systolic diameter (LVESD) which were
expressed as Z-score for body surface area. Subsequently,
fractional shortening (FS) was calculated using the formula
[(LVEDD− LVESD)/LVEDD] ∗100%.
Cardiomyocyte Force Measurements
Single cardiomyocytes were mechanically isolated from cardiac
tissue andmembrane-permeabilized as previously described (van
Dijk et al., 2012). In short, 10–15mg of tissue was defrosted in
4◦C isolation relax solution containing 1mM free Mg, 139.6mM
KCl, 2mM EGTA, 5.95mM ATP, and 10mM imidazole with pH
adjusted to 7.0 with KOH. The tissue was mechanically disrupted
with a Teflon piston for 5–10 s at 900 g to obtain a suspension
of single cells, small clumps of cells and cell fragments. The
cells were incubated with 0.5% TritonX-100 (Millipore) for 5min
at 4◦C to permeabilize the membranes. Triton was removed
from cell suspension by 3 subsequent washes with isolation
relax solution. Cells were kept at 4◦C until measurement on
the same day. Single cardiomyocytes were glued with silicon
based glue (DB-025, Zwaluw, Den Braven) between stainless
steel needles attached to a force transducer (Memscap, AE801)
and a length motor with length controller (Aurora Scientific
Inc., 312-CI filtered at 1,000Hz) while being viewed with an
inverted microscope at 320x magnification. Sarcomere length
was determined by spatial Fourier transformation. Maximal force
(Fmax) and passive force (Fpass) of sarcomeres were measured
at high [Ca2+] and low [Ca2+] (pCa 4.5 and 9.0, respectively).
Force-[Ca2+] curves were constructed at various submaximal
[Ca2+] and are shown as relative forces to Fmax. Myofilament
Ca2+-sensitivity was measured as the [Ca2+] needed to achieve
50% of Fmax (EC50). Length-dependent activation was measured
as the shift in EC50 (1EC50) at a sarcomere length of 1.8 and
2.2µm. In order to correct for differences in protein kinase
A (PKA)-mediated phosphorylation of sarcomeric proteins,
membrane permeabilized cardiomyocytes were incubated with
80 µl 1 unit/µl PKA (P5511, Sigma) and 0.006mM cAMP
(Sigma) in isolation relax solution at 20◦C for 40min prior to
measurement of force development.
Titin Expression and Cardiac Troponin I
Phosphorylation
Titin isoforms were separated on a 1% w/v agarose gel and
stained with SYPRO Ruby protein gel stain (Invitrogen) as
previously described (Warren et al., 2003). All samples were
measured in triplicate and the average of triplicate measurements
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per sample is shown. Phosphorylation of cardiac troponin I
(cTnI) was assessed as previously described (Zaremba et al., 2007;
Najafi et al., 2015). Non-, mono-, and bis-phosphorylated cTnI
(Pierce, MA1-22700) were separated by polyacrylamide bound
Mn2+-phos-tag gel electrophoresis western blotting as previously
described (Najafi et al., 2015). Images were captured with AI600
(GE Healthcare Life Sciences) and analyzed with ImageQuantTL
software (GE Healthcare Life Sciences). Raw blot images of the
representative images can be seen as Supplementary Material
online.
HSP27, HSP70, LC3B-I/II, and p62
Expression
For HSP70 and HSP27 analysis proteins were separated on pre-
cast 10% criterion gels (BioRad) and membranes were incubated
with HSP70 antibody (Enzo) or HSP27 antibody (Cell Signaling),
and GAPDH antibody (Cell signaling) to correct for loading
differences. For LC3B-I and LC3B-II analysis proteins were
separated on pre-cast 8–16% gradient TGX gels (BioRad) and
membranes were incubated with LC3B-I/II antibody. Analysis
of p62 expression was performed by separating proteins on a
12% acrylamide gel and the membrane was cut in two parts.
The upper part was incubated with p62 antibody (Cell signaling)
and the lower part with GAPDH antibody. Data from different
blots was combined by loading the same sample on each gel and
normalizing all for this sample. Images were captured with AI600
(GE Healthcare Life Sciences) and analyzed with ImageQuantTL
software (GE Healthcare Life Sciences). Raw blot images of the
representative images can be seen as Supplementary Material
online.
Electron Microscopy
Cardiac tissue of pediatric CM and control samples were studied
with transmission electron microscopy. Myocardium was fixed
in 2% paraformaldehyde and 2.5% glutaraldehyde in 0.1M
phosphate buffer (pH 7.4), embedded in Epon and cut in 70 nm
sections. The sections weremounted onto formvar-coated copper
grids and stained with a 5% solution of uranyl acetate, followed by
Reynold’s lead citrate. Sections were viewed with Philips CM100
Transmission Electron Microscope. The myofibril density was
determined with ImageJ software and expressed as the percentage
of whole cell area in that picture. The nucleus was excluded from
analysis. For each sample 2–7 different images were analyzed
in order to determine average myofibril density. Maximal and
passive forces were divided by the average myofibril density of
the corresponding sample.
Statistics
Graphpad Prism v7 software was used for statistical analysis.
Means were compared between groups with T-test if data was
normally distributed. Maximal force data was not normally
distributed and therefore means were compared with a Mann-
Whitney test. A p < 0.05 was considered to represent
a statistically significantly difference between groups. N =
number of samples, n = number of cardiomyocytes measured.
Correlation analysis was performed with linear regression
analysis in Graphpad Prism v7 software. A correlation is
considered significant if the slope of the linear regression is
significantly not zero (p< 0.05).
Ethics Statement
This study was approved by the local ethics board of the Erasmus
Medical Center (protocol number MEC-2015-233) and written
informed consent of patients and/or parents was obtained.
Samples were obtained during cardiac transplantation. As we
do not have access to control cardiac tissue from age-matched
individuals, 18 control samples were used from explanted Left
ventricular (LV) heart tissue of healthy donors (age range 21–
65 years old). These healthy donors are people who died from
a non-cardiac cause, typically motor vehicle accidents and were
acquired from the University of Sydney, Australia, with the
ethical approval of the Human Research Ethics Committee
#2012/2814. The codes of control samples are: 6.034, 8.004, 5.086,
3.141, 3.164, 4.049, 4.104, 7.040, 6.020, 5.128, 3.160, 6.008, 7.054,
7.044, 6.056, 3.112, 6.042, and 3.162. All samples were stored in
liquid nitrogen or at−80◦C until use.
RESULTS
Patient Characteristics
Heart tissue was obtained from 9 pediatric patients diagnosed
with DCM and 2 pediatric patients diagnosed with non-
compaction cardiomyopathy during cardiac transplantation. Z-
scores are commonly used to define growth of the heart during
development and are used to distinguish between physiological
and pathological changes in pediatric patients (Chubb and
Simpson, 2012). Patient characteristics are shown in Table 1. LV
end systolic diameter (LVESD) and LV end diastolic diameter
(LVEDD) were increased and LV posterior wall systole (LVPWs)
and LV posterior wall diastole (LVPWd) were decreased, all in
line with the dilated phenotype and diagnosis of DCM.
TABLE 1 | Patient characteristics.
Controls (N = 18) Pediatric CM
(N = 11)
Age 44.1 ± 3.1 years
(N = 18)
10.5 ± 1.3 years
(N = 11)
Sex (% male) 55.6 (N = 18) 45.5 (N = 11)
Time between echo and HTX 15 days (11–64)
LVEDD Z-score 7.9 ± 1.0 (N = 11)
LVESD Z-score 11.7 ± 1.0
(N = 11)
LVPWd Z-score −0.8 ± 0.5
(N = 11)
LVPWs Z-score −3.4 ± 0.5 (N = 8)
FS % at presentation 8 (7–10) (N = 8)
FS % at HTx 15 (8–19) (N = 8)
NT-pro-BNP at HTx 483 (206–1,034)
(N = 10)
Age, LVEDD, LVESD, LVPWd, LVPWs are shown as mean ±SEM. Time between echo
and HTX, FS%, and NT-pro-BNP (pmol/L) are shown as median (interquartile range).
HTX, Cardiac transplantation.
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Hypocontractility and Increased
Myofilament Ca2+-Sensitivity in Pediatric
CM Compared to Controls
Measurements in single cardiomyocytes revealed significantly
lower Fmax (Figure 1A) and Fpass (Figure 1B) in pediatric CM
compared to controls. A leftward shift of the force-[Ca2+] curve
indicated an increased myofilament Ca2+-sensitivity in pediatric
CM compared to controls (Figure 1C). The combination of
reduced Fmax, reduced Fpass, and increased Ca
2+-sensitivity
of myofilaments results in lower force development at high
(saturating) [Ca2+], lower force at very low [Ca2+], and
higher force development at intermediate [Ca2+], respectively
(Figure 1D). The increase in myofilament Ca2+-sensitivity was
evident at both sarcomere lengths (1.8 and 2.2µm; Figure 1E).
The slope of the curve in Figure 1E represents the ability to
increase contractility upon stretch and is called length-dependent
activation. Length-dependent activation is the cellular basis of
the Frank-Starling mechanism. Length-dependent activation is
often expressed as the shift in calcium sensitivity upon stretch.
Pediatric CM cardiomyocytes showed an impaired length-
dependent activation depicted as a decreased 1EC50 compared
to control cardiomyocytes (Figure 1F).
Titin Isoform Composition Variation in
Pediatric CM Has Limited Effect on
Contractility
A shift toward more N2BA titin isoform has been shown to
lower Fpass (Granzier and Irving, 1995; Makarenko et al., 2004;
Nagueh et al., 2004) and reduce length-dependent activation
(Fukuda et al., 2003). Analysis of titin isoform composition did
not reveal a difference in the N2BA/N2B ratio between pediatric
CM and controls (Figures 2A,B). However, a wide variation in
titin isoform composition was observed in the pediatric CM
group (Figure 2B). Since titin isoform composition has been
shown to affect length-dependent activation we divided samples
into a group that showed a high N2BA/N2B ratio (N2BA/N2B
> 0.65) and a low N2BA/N2B ratio (N2BA/N2B < 0.4). Both
groups showed lower1EC50 compared to controls and there was
no significant difference in 1EC50 between both pediatric CM
groups. However, the group of samples with a high N2BA/N2B
ratio showed a slightly but non-significantly greater reduction in
1EC50 than the group of samples with a low N2BA/N2B ratio
(Figure 2C). In addition, 1EC50 did not significantly correlate
with the N2BA/N2B ratio (Figure 2D). Accordingly, Fpass was
reduced to the same extent in the groups of pediatric CM samples
with a relatively high N2BA/N2B ratio (N2BA/N2B > 0.65) and
a low N2BA/N2B ratio (N2BA/N2B < 0.4) (Figure 2E). This
indicates that other factors underlie the reduction of Fpass.
The wide spread in age of our patient population was not
responsible for the spread of titin isoform composition since
no correlation was found between age and N2BA/N2B ratio
(Figure 2F). We observed a significant correlation between
N2BA/N2B and LVPWs (Figure 2J) in which a high N2BA/N2B
ratio was associated with a less negative LVPWs z-score. This
implies that patients with more compliant titin isoform had a
smaller reduction in systolic LV wall thickness. No significant
correlation was found between N2BA/N2B and LVEDD z-score
(Figure 2G), LVESD z-score (Figure 2H) or LVPWd z-score
(Figure 2I).
Lower Phosphorylation of cTnI in Pediatric
CM Compared to Controls
Phosphorylation of cTnI is reduced in various forms of
adult heart failure and causes increased myofilament Ca2+-
sensitivity (van Dijk et al., 2009; Sequeira et al., 2013; Beqqali
et al., 2016; Bollen et al., 2017b). In line with published
data in adult DCM (Wijnker et al., 2014; Beqqali et al.,
2016; Bollen et al., 2017b), phosphorylation of cTnI was
significantly lower in pediatric CM compared to controls
(Figures 3A–C). PhosTag analysis showed separation of non-,
mono- and bisphosphorylated cTnI (Figure 3D). While controls
showed predominantly bisphosphorylated cTnI, in pediatric
CM patients the non-phosphorylated cTnI was more prevalent
(Figure 3E). In order to confirm that cTnI hypophosphorylation
causes the high myofilament Ca2+-sensitivity in pediatric CM
samples, force measurements were repeated after incubation with
exogenous PKA which phosphorylates cTnI. Both myofilament
Ca2+-sensitivity and length-dependent activation normalized
to control values upon incubation with exogenous PKA
(Figures 4A,B). With normalized phosphorylation status of
cTnI, there was no difference in 1EC50 between the group
of pediatric CM samples with a low N2BA/N2B ratio and a
high N2BA/N2B ratio (Figure 4C). Also after incubation with
exogenous PKA, 1EC50 did not significantly correlate with
N2BA/N2B ratio (Figure 4D). The slope of the curve which
indicates the strength of the correlation, was small and non-
significant at baseline (Figure 2D) and was even smaller after
incubation with exogenous PKA (Figure 4D). This implies that
any effect of N2BA/N2B ratio on length-dependent activation
was diminished upon incubation with exogenous PKA. Fpass also
remained low after incubation with exogenous PKA (Figure 4E).
In addition, no difference in Fpass was observed between PKA-
treated groups of pediatric CM samples with different N2BA/N2B
ratios (Figure 4F).
Decreased Myofibril Density Underlies the
Hypocontractility in Pediatric CM
As titin isoform composition was ruled out as cause of the
observed decrease in Fpass and Fmax, we determined myofibril
density with transmission electron microscopy. We observed a
significantly lower myofibril density in pediatric CM compared
to controls (Figures 5A,B). Correction of Fmax for myofibril
density eliminated the difference between pediatric CM and
controls indicating the hypocontractility was due to myolysis or
the inability to create sufficient myofibrils (Figure 5C). Also Fpass
of pediatric CM cardiomyocytes was restored to control values
after correction for myofibril density (Figure 5D).
Protein Quality Control System Is
Unaltered in Pediatric CM
We then studied whether changes in the protein quality control
system occurred, which may underlie reduced myofibril density.
Heat shock proteins (HSPs) are upregulated in response to
cellular stress in order to prevent protein denaturation, and aid in
refolding of misfolded proteins. We did not find an induction of
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FIGURE 1 | Baseline characteristics. (A) Maximal force was significantly lower in pediatric CM (23.8 ± 1.1, N = 11, n = 78) compared to controls (37.4 ± 2.6, N = 6,
n = 27, p < 0.0001). (B) Fpass was significantly lower in pediatric CM (N = 11, n = 40) compared to controls (N = 10, n = 29, p < 0.0001) over a range of sarcomere
lengths. (C) A leftward shift of the relative force vs. [Ca2+] indicates higher myofilament Ca2+-sensitivity in pediatric CM (N = 11, n = 38) compared to controls (N = 5,
n = 12, p < 0.0001). (D) The absolute force development over a range of [Ca2+] showed pediatric CM have impaired maximal force development at saturating [Ca2+],
increased force development at lower [Ca2+] and a decreased Fpass. (E) Ca
2+-sensitivity was significantly higher at sarcomere lengths of 1.8 and 2.2µm in pediatric
CM (N = 11, n = 38) compared to controls (N = 5, n = 12, p < 0.0001). (F) Length-dependent activation, measured as 1EC50 was significantly lower in pediatric CM
(0.60 ± 0.05, N = 11, n = 38) compared to controls (0.86 ± 0.09, N = 5, n = 12, p = 0.007). N, number of samples; n, number of cardiomyocytes measured.
Measurements obtained from samples derived from patients with non-compaction cardiomyopathy are indicated in gray (A,F). **p <0.01, ****p < 0.0001 vs. controls.
HSP70 (Figures 6A,C) or the cytoskeletal HSP27 (Figures 6B,D)
in our pediatric CM group compared to controls. We did find
a significantly decreased LC3B1/LC3B-II ratio (Figures 6E,G),
which implies an induction of autophagy. However, p62,
another autophagy marker, was not upregulated in pediatric CM
compared to controls (Figures 6F,H).
DISCUSSION
Characterization of end-stage pediatric CM myocardium
revealed reduced active and passive cardiomyocyte force
development, high myofilament Ca2+-sensitivity and a blunted
length-dependent activation compared to adult non-failing
controls. High myofilament Ca2+-sensitivity and blunted length-
dependent activation were explained by low PKA-mediated
phosphorylation of cTnI, which is a general feature observed in
cardiac disease. We showed that the decrease in Fmax and Fpass
was due to decreased myofibril density.
No Indications for Alterations in Protein
Quality Control System in Pediatric CM
We observed a decrease in myofibril density which was causal to
the hypocontractile cellular phenotype in end-stage pediatric CM
compared to adult non-failing controls. A reduction in myofibril
density and subsequent decreased maximal force development
has been observed in adult cardiomyopathy due to specific
mutations (Witjas-Paalberends et al., 2013; Bollen et al., 2017b;
Hoorntje et al., 2017). Maximal force development was not
reduced in adult idiopathic DCM or in DCM caused by cardiac
troponin I and T mutations (Bollen et al., 2017a,b). Even
though these studies did not measure myofibril density, these
findings imply that the hypocontractility observed in pediatric
CM samples is not a general DCM feature.
It has been reported that myofibril density is lower during
prenatal development and increases in neonatal cardiac tissue
(Racca et al., 2016). Force development was also lower in prenatal
and neonatal myofibrils compared to adult myofibrils (Racca
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FIGURE 2 | Titin isoform composition has limited effect on contractility in pediatric CM. (A) Separation of titin N2BA and N2B with gel electrophoresis. (B) N2BA/N2B
ratio was not significantly different between pediatric CM (0.62 ± 0.12, N = 11) and controls (0.53 ± 0.03, N = 15). (C) Length-dependent activation was mostly
impaired in pediatric CM patients who had higher N2BA/N2B ratio (N2BA/N2B > 0.65, N = 5, n = 19) compared to pediatric CM patients who had lower N2BA/N2B
ratio (N2BA/N2B < 0.4, N = 6, n = 19). Dotted line indicates control values. (D) Mean 1EC50 per sample plotted against the N2BA/N2B ratio did not show a
significant correlation between 1EC50 and N2BA/N2B. (E) There was no difference in Fpass between pediatric CM patients who had higher N2BA/N2B ratio
(N2BA/N2B > 0.65, N = 5, n = 18) and pediatric CM patients who had lower N2BA/N2B ratio (N2BA/N2B < 0.4, N = 6, n = 22). (F) N2BA/N2B ratio was not
significantly related to age. (G) No significant correlation was found between N2BA/N2B and LVEDD z-score. (H) No significant correlation was found between
N2BA/N2B and LVESD z-score. (I) No significant correlation was found between N2BA/N2B and LVPWd z-score. (J) A significant correlation was found between
N2BA/N2B ratio and LVPWs z-score (p < 0.05). N, number of samples; n, number of cardiomyocytes measured. Measurements obtained from samples derived from
patients with non-compaction cardiomyopathy are indicated in gray (B–D).
et al., 2016). To our knowledge no reports about myofibril density
in healthy individuals in the age range we studied are available.
The pediatric samples we studied were derived from patients
with an age range between 3 and 15 years old. We did not find
an age-dependent change in myofibril density in our pediatric
patients. This implies that it is unlikely that the reduced myofibril
density we observed in the pediatric CM samples compared to
adult control samples is a reflection of a lower myofibril density
at young age.
Reduced HSP expression has been shown to increase cardiac
damage after brief ischemia, and pretreatment with heat to
induce HSPs reduced cardiac damage after infarction. However,
in conditions of continuous stress as is the case in DCM, the HSP
responses are less clear. HSP27 has been shown to be upregulated
in adult DCM and not in ischemic heart disease (Knowlton
et al., 1998). There are conflicting reports about HSP70 in adult
DCM ranging from no change (Knowlton et al., 1998), to an
increased expression (Barrans et al., 2002). HSPs may lose their
responsiveness in conditions of continuous cardiac stress. We
did not find an induction of heat shock response, and we also
did not find more autophagosomes in pediatric CM compared
to controls. Future studies are warranted to reveal if reduced
myofibril density in pediatric CM is due to an inability of
cardiomyocytes to increase myofibril synthesis and/or is caused
by increased myofibril degradation.
Low PKA-Mediated Phosphorylation, High
Myofilament Ca2+-Sensitivity and Blunted
Length-Dependent Activation
In line with what has been found in adult DCM patients
(van Dijk et al., 2009; Bollen et al., 2017b), we observed
decreased cTnI phosphorylation which caused an increase in
Ca2+-sensitivity in end-stage pediatric CM patients compared
to controls. Hypophosphorylation of cTnI has been shown to
occur in various forms of heart failure. It is likely due to
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FIGURE 3 | Hypophosphoryalation in pediatric CM compared to controls. (A) ProQ staining identifying phosphorylated proteins of pediatric CM and control samples.
(B) Corresponding SYPRO staining identifying proteins of pediatric CM and control samples. (C) cTnI phosphorylation was significantly lower in pediatric CM (N = 11)
compared to controls (N = 13, p < 0.0001). (D) Phostag showed separation of non-, mono-, and bisphosphorylated cTnI. (E) While controls (N = 11) showed
predominantly mono- and bisphosphorylated cTnI, pediatric CM samples (N = 11) showed mostly non-phosphorylated cTnI. Measurements obtained from samples
derived from patients with non-compaction cardiomyopathy are indicated in gray. ****p < 0.0001 vs. controls.
desensitization of the β-adrenergic receptor signaling pathway
and subsequent decrease in PKA-mediated phosphorylation
(Harding et al., 1994). Hypophosphorylation of cTnI has
been shown to underlie a blunted length-dependent activation
(Fukuda et al., 2009; Wijnker et al., 2013, 2014). Treatment
of cardiomyocytes with exogenous PKA corrected both Ca2+-
sensitivity of myofilaments and length-dependent activation,
independent of the titin isoform composition present in the
heart.
In early postnatal life a slow skeletal isoform of TnI (ssTnI)
is present in the heart and this isoform has been shown
to increase Ca2+-sensitivity (Fentzke et al., 1999). However,
the ssTnI isoform can no longer be detected at day 14 after
birth in mice and has been replaced by cTnI (Huang et al.,
1999). It has been shown that ssTnI is not responsive to PKA
treatment (Fentzke et al., 1999). Since we showed that blunted
length-dependent activation and high Ca2+-sensitivity could be
normalized to adult non-failing controls with exogenous PKA
treatment this implies that ssTnI is either not present or at
such low levels in the studied pediatric CM samples that its
effect on Ca2+-sensitivity and length-dependent activation can be
neglected.
Titin Isoform Composition Is Highly
Diverse in Pediatric CM
Titin is composed of two isoforms, a compliant N2BA isoform
and a stiff N2B isoform. Various animal models, including
pigs, rats, mice, and rabbits, have shown that a very compliant
fetal isoform is expressed early in life and disappears quickly
after birth (Lahmers et al., 2004). In pigs, which heart is often
considered to represent a human heart better than rodents, this
fetal isoform is completely replaced by the adult isoforms at
180 days after birth. An increase in N2BA/N2B ratio has been
reported in various forms of heart failure including adult DCM
(Makarenko et al., 2004; Nagueh et al., 2004; Bollen et al., 2017b)
and is considered a general hallmark of DCM. However, in our
pediatric CM study population we observed a wide variation of
N2BA/N2B ratios: 5 patients showed a higher N2BA/N2B ratio,
while 6 patients showed a normal or even lower N2BA/N2B ratio
compared to controls. The shift in titin isoform composition in
DCM is not due to re-expression of the fetal isoform which is
of a significantly larger size (Bollen et al., 2017a). Re-expression
of this larger titin isoform has been observed in DCM, but only
in samples or animal models in which a mutation was found or
introduced in the gene encoding the splicing regulator of titin:
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FIGURE 4 | Restoration of sarcomere function after incubation with exogenous PKA. (A) Exogenous PKA restored myofilament Ca2+-sensitivity in pediatric CM
(N = 11, n = 30) to control (n = 5, n = 12) values. (B) Exogenous PKA eliminated the difference in length-dependent activation (1EC50) between pediatric CM
patients with higher N2BA/N2B ratio (N2BA/N2B > 0.65, N = 5, n = 14) and pediatric CM patients who had lower N2BA/N2B ratio (N2BA/N2B < 0.4, N = 6, n = 16)
(shown relative to control value). Dotted line indicates control values. (C) There was no difference between patients with high or low N2BA/N2B ratio with respect to
1EC50 after incubation with exogenous PKA. (D) Mean 1EC50 per sample measured after incubation with exogenous PKA plotted against the N2BA/N2B ratio did
not show a significant correlation between 1EC50 and N2BA/N2B. (E) Exogenous PKA did not affect Fpass in controls or pediatric CM. Fpass remained significantly
lower in pediatric CM compared to controls. (F) There was no difference in Fpass after incubation with exogenous PKA between pediatric CM patients who had higher
N2BA/N2B ratio (N2BA/N2B > 0.65, N = 5, n = 13) and pediatric CM patients who had lowerN2BA/N2B ratio (N2BA/N2B < 0.4, N = 6, n = 18). N, number of
samples; n, number of cardiomyocytes measured. Measurements obtained from samples derived from patients with non-compaction cardiomyopathy are indicated in
gray (B–D).
FIGURE 5 | Myofibril density is decreased in pediatric CM. (A) Electron microscopy images of 2 control samples and 2 pediatric CM samples. (B) Myofibril density
was significantly lower (P < 0.0001) in pediatric CM (N = 10, 45.3 ± 1.4%) compared to controls (N = 10, 57.3 ± 1.8%). (C) Fmax normalized for myofibril density of
corresponding sample did not differ significantly between pediatric CM (N = 10, n = 71) and controls (N = 6, n = 27). (D) Fpass normalized for myofibril density of
corresponding sample was not significantly different between pediatric CM (N = 10, n = 37) and controls (N = 9, n = 25). N, number of samples; n, number of
cardiomyocytes measured. Measurements obtained from samples derived from patients with non-compaction cardiomyopathy are indicated in gray. ****p < 0.0001
vs. controls.
RBM20 (Methawasin et al., 2014; Beqqali et al., 2016). On average
we observed no significant change in titin isoform composition in
pediatric CM compared to controls. The pediatric CM samples
in this study did not differ in location of the titin isoforms in the
gels compared to adult non-failing controls. This implies that the
fetal isoform is not present as this isoform should be located at
a much higher position in the gel. In addition, we did not find a
significant correlation between age and N2BA/N2B ratio which
implies that the wide variation in N2BA/N2B ratio we observed
was not due to the spread in age within the pediatric CM group
or biased by ongoing developmental changes in childhood.
An increase in N2BA titin has been shown to cause a blunted
length-dependent activation in animal models,(Fukuda et al.,
2003, 2009; Inoue et al., 2013; Kobirumaki-Shimozawa et al.,
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FIGURE 6 | Protein quality control system in pediatric CM. (A) Representative blot images for HSP27 expression. (B) Representative blot images for HSP70
expression. (C) Expression of HSP27 was not altered in pediatric CM (N = 11) compared to controls (N = 11). (D) Expression of HSP70 was not altered in pediatric
CM (N = 11) compared to controls (N = 11). (E) Representative blot images for LC3BI and LC3B-II expression. (G) Expression of LC3B-I/LC3-BII was significantly
(p <0.05) reduced in pediatric CM (N = 11) compared to controls (N = 11). (F) Representative blot images for p62 expression. (H) Expression of p62 was not altered
in pediatric CM (N = 11) compared to controls (N = 7). GAPDH was used a loading control in the HSP27, HSP70, and p62 blots. Measurements obtained from
samples derived from patients with non-compaction cardiomyopathy are indicated in gray. *p < 0.05, vs. controls.
2014) while we only observed a modest effect of N2BA on length-
dependent activation of myofilaments in human pediatric CM
samples. The length-dependent increase in myofilament Ca2+-
sensitivity was slightly, though not significantly lower in pediatric
CM samples with a high N2BA/N2B ratio compared to samples
with a low N2BA/N2B ratio. There was no significant difference
in 1EC50 between pediatric CM samples with a low or high
N2BA/N2B ratio and both groups showed a reduced 1EC50
compared to controls. This implies that the blunted length-
dependent activation observed in pediatric CM samples was not
solely caused by samples with a high N2BA/N2B ratio. Length-
dependent activation of myofilaments was normalized in all
pediatric CM samples to control values after incubation with
PKA which indicates that the increase in compliant titin only
contributes to the impairment of length-dependent activation
of myofilaments when cTnI is hypophosphorylated. This is in
line with what has been reported in adult DCM (Beqqali et al.,
2016; Bollen et al., 2017b). While increased N2BA/N2B ratio has
been associated with impaired systolic function, a lowN2BA/N2B
ratio is associated with improved diastolic function. A positive
correlation between N2BA/N2B and peak oxygen consumption,
a measure for exercise tolerance, in DCMpatients has been found
(Nagueh et al., 2004). We observed that a high N2BA/N2B ratio
coincided with a smaller reduction in LV wall thickness during
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systole (LVPWs). An increase in N2BA/N2B ratio may represent
a compensatory mechanism in order to cope with altered cardiac
stress. The correlation between increased N2BA/N2B ratio and
a smaller reduction in LVPWs may imply that an increase in
N2BA/N2B ratio has a limited impact on sarcomere function in
end-stage pediatric CM. This is in line with the moderate effect
of increased N2BA/N2B on the impairment of length-dependent
activation. However, it should be stated that all studied heart
tissue was derived from end-stage pediatric CM patients and
therefore might suffer from severe cardiac remodeling. It might
be possible that N2BA/N2B aids in this remodeling in a positive
way by creating more flexibility in the sarcomeric structure to
function under overstretched conditions at the initial disease
stage.
Cardiac Remodeling: Friend or Foe?
The increase in compliant titin might not have a direct causal
role in disease pathogenesis, but may rather represent an adaptive
response in order to cope with altered cardiac demand. The
inability of pediatric CM patients to upregulate N2BA expression
might be a reflection of their limited capability to adapt to
altered cardiac demands. This is in line with Patel et al. who
recently published limited adverse remodeling in pediatric CM
patients compared to adult onset DCM (Patel et al., 2017).
They showed that hypertrophy and perivascular and interstitial
fibrosis was increased in adult DCM but not in pediatric
CM patients compared age-matched controls. In addition, they
showed sarcomere thickness was increased in adult DCM, but not
in pediatric CM (Patel et al., 2017). Limited cardiac remodeling
in pediatric CM patients might hamper the hearts to cope with
altered cardiac demands. If the limited adaptive capabilities of the
heart are indeed causal to the early and progressive disease onset
warrants further research.
Limitations
We have compared end-stage pediatric DCM patients with
healthy adult controls since acquisition of healthy control tissue
of children is near impossible. However, we did not find any
correlations between age and protein expression or sarcomere
function. Therefore we believe the observed changes are not
related to difference in age.
Three patients were supported with a ventricular assist device
(VAD) prior to transplantation. The duration of VAD support
was short (1–2 months). We did not see a difference in any
parameter between patients that were supported with a VAD
and patients that were not supported prior to transplantation.
However, we cannot exclude that VAD also affected cardiac
remodeling.
CONCLUSION
In summary, we show that end-stage pediatric CM patients
harbor similar changes in protein modifications and sarcomeric
function compared to adult DCM. Hypophoshorylation of cTnI,
most likely due to secondary disease remodeling and desensitized
β-adrenergic receptor signaling, led to increased Ca2+-sensitivity
and blunted length-dependent activation of myofilaments. We
did not find the consistent upregulation of compliant N2BA
titin isoform that has been observed in adult DCM. Increased
N2BA/N2B ratio was significantly related to a lower LVPWs z-
score. The limited cardiac remodeling in pediatric CM patients,
illustrated in this study by the limited shift in titin isoform
composition, might have hampered the ability to cope with
altered cardiac demands and might have contributed to their
early disease onset and progression. We found cardiomyocyte
hypocontractility which was caused by a significant decrease
in myofibril density. The severe reduction in force generating
capacity of cardiomyocytes may underlie the fast progression of
cardiac disease in pediatric patients.
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